Creative Funding Options For China; Investors Battle Perception of Home Court Advantage
This article was originally published in PharmAsia News
Executive Summary
The growth in available government funding for pharmaceutical companies in China is creating a snowball of investment from domestic and multinational pharma companies more willing to overcome intellectual property concerns
You may also be interested in...
Is Beta Pharma The Best Model For Innovation In China? Views From Lilly Asia Ventures And Other VCs
Top fund managers share thoughts on innovation and investment in China and predict who will be the next big winners.
Is Beta Pharma The Best Model For Innovation In China? Views From Lilly Asia Ventures And Other VCs
Top fund managers share thoughts on innovation and investment in China and predict who will be the next big winners.
Meet China’s New Innovators: Beta Pharma Redefines Innovation With “Me-Too, Me-Better” Strategy
Beta Pharma is likely to see $50 million in the first year of sales for icotinib, the first NCE cancer drug developed in China.